Innovations in HIV Testing (TI)

Innovations in HIV Testing to Enhance Care for Young Women and Their Peers and Partners

The investigators propose to improve HIV prevention and care through expanding HIV testing options to include self-testing for young women, their peers and their sex partners, and by facilitating linkage to care.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The investigators propose to improve HIV prevention and care through expanding HIV testing options to include self-testing for young women, their peers and their sex partners, and by facilitating linkage to care. In this study the investigators proposed two phases. The first phase, previously completed, is formative and involved two parts: 1) conducting formative qualitative research to understand perceptions of HIV testing and HIV self-testing in the study population and 2) conducting observed HIV self-testing to better understand any challenges with self-testing and the materials needed to make the process clear. The second phase of the study is a randomized controlled trial where the investigators will randomize approximately 400 young women to receive either 1) CHOICE of self-testing or clinic-based HIV Counseling and Testing (HCT) or 2) clinic based HCT. Once young women have been randomized, they will be asked to recruit up to 4 peers or male sex partners to test with the method of their randomization group.

Study Type

Interventional

Enrollment (Actual)

898

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Mpumalanga
      • Acornhoek, Mpumalanga, South Africa
        • Medical Research Council/Wits University Rural Public Health and Health Transitions Research Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Eligibility Inclusion Criteria Index:

  • Females ages 18-26
  • Have had sex in the past 3 months and plan to have sex again in the next 3 months
  • Planning on staying in the Agincourt Health and Demographic Surveillance System (AHDSS) area for the next nine months
  • Able and willing to provide informed consent
  • Willing to comply with study procedures
  • Not known to be HIV positive (not reporting a previous positive test)

Eligibility Inclusion Criteria Peer/Partner:

  • Females and Males ages 18 and older
  • Able and willing to provide informed consent
  • Willing to comply with study procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Choice
Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
This is an oral swab in home HIV test.
Receiving Counseling and Testing for HIV at the clinic.
Active Comparator: HIV Counseling and Testing
Clinic Based HIV Counseling and Testing (HCT)
Receiving Counseling and Testing for HIV at the clinic.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of index reporting testing uptake
Time Frame: 3 months post randomization
Compare between the two study arms the proportion of testing uptake at 3 months post-randomization. Testing uptake is defined for HCT as self-report of going to the clinic and testing; and for self-test as self-report of using a self-test kit.
3 months post randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of peer/partner referrals by the index
Time Frame: 12 months post randomization
Compare between the two studies arms the number of self test kits and HCT cards distributed by the index.
12 months post randomization
Proportion of peer/partners reporting testing uptake
Time Frame: 12 months post randomization
Compare between the two study arms the proportion of testing uptake by peers/partners. Testing uptake is defined for HCT as self-report of going to the clinic and testing; and for self-test as self-report of using a self-test kit.
12 months post randomization
Proportion of index and peer/partners who obtain a confirmatory test, start Antiretroviral Treatment (ART) if HIV+, and obtain their Cluster of Differentiation 4 (CD4) count if HIV+
Time Frame: 12 months post randomization
Among participants who test positive (young women, peers and sex partners), the investigators will examine uptake of linkage to care.
12 months post randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2016

Primary Completion (Actual)

October 31, 2018

Study Completion (Actual)

October 31, 2018

Study Registration Dates

First Submitted

May 19, 2017

First Submitted That Met QC Criteria

May 19, 2017

First Posted (Actual)

May 22, 2017

Study Record Updates

Last Update Posted (Actual)

August 9, 2019

Last Update Submitted That Met QC Criteria

August 6, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 15-1361b
  • 5R01HD083033 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Human Immunodeficiency Virus

Clinical Trials on Oraquick HIV Self Test

Search Similar Trials